JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Aytu BioScience Inc

Suletud

2.37 3.49

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.36

Max

2.43

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+290.38% upside

Aytu BioScience Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. veebr 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8. veebr 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8. veebr 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8. veebr 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. veebr 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8. veebr 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8. veebr 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8. veebr 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8. veebr 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7. veebr 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. veebr 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. veebr 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. veebr 2026, 02:46 UTC

Omandamised, ülevõtmised, äriostud

Big Money, High Anxiety -- Barrons.com

6. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. veebr 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. veebr 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. veebr 2026, 21:17 UTC

Tulu

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. veebr 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. veebr 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. veebr 2026, 21:13 UTC

Tulu

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. veebr 2026, 21:13 UTC

Tulu

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. veebr 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. veebr 2026, 20:34 UTC

Tulu

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Aytu BioScience Inc Prognoos

Hinnasiht

By TipRanks

290.38% tõus

12 kuu keskmine prognoos

Keskmine 9.33 USD  290.38%

Kõrge 13 USD

Madal 7 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Aytu BioScience Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Finantsandmed

$

help-icon Live chat